Approvals

January 24, 2024

New Findings on Eplontersen for Hereditary Transthyretin-Mediated Amyloid Polyneuropathy (ATTRv-PN)

Hereditary Transthyretin-Mediated Amyloid Polyneuropathy (ATTRv-PN) is a rare, progressive, and often fatal genetic disease caused by mutations in the transthyretin (TTR) gene. It results in the accumulation of amyloid fibrils in the nerves, heart, and other organs, leading to symptoms such as polyneuropathy and cardiomyopathy, as well as other serious complications.
New Findings on Eplontersen for Hereditary Transthyretin-Mediated Amyloid Polyneuropathy (ATTRv-PN)
This website uses cookies to improve your experience. By using this website you agree to our Cookie Policy.
Read more